We are live on
!
Find out more
SVCM
Saturn V Capital Management Portfolio holdings
AUM
$552M
1-Year Est. Return
551.78%
This Fund
S&P 500
This Quarter
Est. Return
+40.7%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$22.3M
(+9.3%)
Cap. Flow
-$22.8M
Cap. Flow
% of AUM
-8.73%
Top 10 Holdings %
Top 10 Hldgs %
74.44%
Holding
26
New
6
Increased
7
Reduced
10
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$19.2M |
| 2 |
MRUS
Merus
MRUS
|
+$8.16M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$7.25M |
| 4 |
Disc Medicine
IRON
|
+$3.32M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$3.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$14.4M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.8M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$10.4M |
| 4 |
Biogen
BIIB
|
+$7.91M |
| 5 |
Cogent Biosciences
COGT
|
+$7.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
TC
BT
CA
IQI
BCM
TC
LWP
AI
Saturn V Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Saturn V Capital Management held 26 positions worth $261M, up 9.3% from $239M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Saturn V Capital Management withdrew a net $22.8M in Q4 2023, closing 3 positions and reducing 10 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $14.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Saturn V Capital Management opened a new position in Apellis Pharmaceuticals worth $8.56M.
- Saturn V Capital Management's largest Q4 2023 buy was Apellis Pharmaceuticals: 142,927 shares worth $8.56M.
- Saturn V Capital Management added most to argenx in Q4 2023, an estimated $19.2M increase.
- Saturn V Capital Management's biggest Q4 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $10.4M.
- Saturn V Capital Management fully exited Sarepta Therapeutics in Q4 2023, selling an estimated $14.4M.
- Saturn V Capital Management's ten largest holdings make up 74% of its $261M portfolio in Q4 2023.
- Saturn V Capital Management opened 6 new positions and closed 3 in Q4 2023.
- Saturn V Capital Management's portfolio value rose 9.3% quarter-over-quarter to $261M.
Based on Saturn V Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.